MINDCURE Launches Second Stage of Manufacturing Synthetic Ibogaine for Use in Psychedelic Clinical Research

MINDCURE’s proprietary ibogaine manufacturing has reached the second stage of development: assessing the quality of its synthetic ibogaine.

Read more
New study sheds light on how LSD’s entropic effects on the brain impact language production

Language produced under the influence of the psychedelic drug lysergic acid diethylamide displays increased levels of entropy and reduced semantic coherence, according to new research published in the journal Consciousness and Cognition.

Read more
Colombia Lifts Ban on Cannabis Flower Exports

Colombia’s President Ivan Duque last week signed a decree lifting the export ban on dried cannabis flower from the South American country, Reuters reports.

Read more
Field Trip Health Ltd. to Commence Trading on the NASDAQ on July 29, 2021 Under the Symbol FTRP

Field Trip Health to commence trading on the NASDAQ on July 27th under the symbol “FTRP”.

Read more
Cybin Announces Overnight Marketed Public Offering of Common Shares

Cybin Inc is seeking to raise capital with an overnight offering of common shares. Pricing and size of the offering to be determined.

Read more
Will The Covid-19 Pandemic Be A Turning Point For Psychedelic Medicine?

The Mental Health Crisis has been ignored for decades. Covid-19 has made this mental health catastrophe much worse — and people are now starting to notice.

Read more
Cybin Announces Size and Pricing of Previously Announced Overnight Marketed Public Offering of Common Shares

Cybin’s new financing is priced at CAD$3.40. The Company intends to issue 8.8 million new units for total proceeds of CAD$30 million.

Read more
MindMed Announces Initiation of Phase 1 Clinical Trial of Intravenous DMT

MindMed is preparing to commence a Phase I clinical trial on the safety/tolerance of intravenous DMT.

Read more
atai Life Sciences launches InnarisBio, in partnership with the University of Queensland, with the aim to develop a more effective nose-to-brain delivery method for atai’s platform of mental health therapeutic programs

Atai Life Sciences announces the launch of a new intranasal drug delivery system, InnarisBio, based on sol-gel technology.

Read more
Substance Abuse: Global Plague, A Pot Of Gold For Psychedelic Stocks

We explain why addiction therapy likely offers the greatest long-term commercialization potential within the psychedelic drug industry.

Read more



( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )